about
Hepatitis C: a review for primary care physiciansThe cost-effectiveness of Vancouver's supervised injection facilityUpdate on the clinical use of buprenorphine: in opioid-related disordersRisk factors for hepatitis C virus infection among street youthsGeographic integration of hepatitis C virus: A global threat.Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youthGenetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study.The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.Prevalence and incidence of hepatitis C virus infection among Aboriginal young people who use drugs: results from the Cedar Project.Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid Use Disorder Treated with Methadone.Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis CImproving access to care by allowing self-referral to a hepatitis C clinic.Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.Prevalence and incidence of hepatitis C virus in hemodialysis patients in British Columbia: Follow-up after a possible breach in hemodialysis machines.Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes.
P2860
Q22306040-4213566C-5880-40CD-84BE-6B0E28794069Q24657903-4BC47B78-0556-4082-958F-D2E240BBBB72Q26829140-A7312ABD-8357-4B23-98FF-63D88AC22148Q28354457-9B4528E3-8703-45F8-AF28-F36B0BF33E1DQ30395543-8FACEE1F-4E6E-4082-B9E5-D18C3F8C4201Q33996279-8A7E9280-99CE-4774-A8E5-ED82680DE815Q34109820-792FB84E-97E6-4CE4-834A-AF1D67DCBC3CQ34226309-DEFC97BA-368F-4205-86E8-EF2F59E42A44Q34954338-15B764B3-4406-4798-81D5-D8971857092FQ36272393-A06D13B4-068B-4F3D-B69C-BCF9F305A541Q36274331-1C849C08-EF37-448C-BB8F-9A74261FC294Q36787556-C8BABCC6-27B8-4222-8937-504763F9AC17Q37144240-F76C641B-DAC1-4A94-A6F4-ABAEAD97E760Q37291694-C2CF1DE1-E9CF-4EAA-9C35-0F1CC52FF2ACQ38873165-68A589ED-FAA9-4D2F-8037-E6564643B859Q43100447-B8625C0F-32A0-4E38-BCCE-3DD7D931D2BFQ45847009-CB81E1B3-5A90-4F8C-9396-F2198050FA53
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Current status of hepatitis C in Canada.
@ast
Current status of hepatitis C in Canada.
@en
Current status of hepatitis C in Canada.
@nl
type
label
Current status of hepatitis C in Canada.
@ast
Current status of hepatitis C in Canada.
@en
Current status of hepatitis C in Canada.
@nl
prefLabel
Current status of hepatitis C in Canada.
@ast
Current status of hepatitis C in Canada.
@en
Current status of hepatitis C in Canada.
@nl
P2093
P356
P1476
Current status of hepatitis C in Canada
@en
P2093
P304
S10-5, S10-6
P356
10.1007/BF03405100
P478
91 Suppl 1
P577
2000-07-01T00:00:00Z